- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.10. | FluoGuide A/S: FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma | 285 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 5, 2026 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotechnology company focused on precision cancer surgery... ► Artikel lesen | |
| 02.10. | FluoGuide A/S: FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company | 580 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 2, 2026 / FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration... ► Artikel lesen | |
| 25.08. | Earnings Call Transkript: FluoGuide treibt US-Krebsstudie im ersten Halbjahr 2026 voran | 1 | Investing.com Deutsch | ||
| 25.08. | FluoGuide A/S Q2 Loss Increases | 2 | RTTNews | ||
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 25.08. | FluoGuide A/S Publishes Interim Report for Q2 2026 | 352 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 25, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 30 June 2026. The Q2 report is... ► Artikel lesen | |
| 12.08. | Invitation to FluoGuide A/S Live Webcast on 25 August 2026 | 336 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / August 12, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026.Later that day, CEO Morten Albrechtsen and CFO Ole... ► Artikel lesen | |
| 01.07. | FluoGuide A/S: Update on 2026 Outlook and Company Progress | 458 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an... ► Artikel lesen | |
| 29.06. | FluoGuide A/S: FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial | 431 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.05. | FluoGuide A/S Publishes Interim Report for Q1 2026 | 459 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available... ► Artikel lesen | |
| 13.05. | Invitation to FluoGuide A/S Live Webcast on 27 May 2026 | 373 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 10.04. | FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG | 270 | GlobeNewswire (Europe) | Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer.
The interim data from... ► Artikel lesen | |
| 25.03. | Minutes from Annual General Meeting in FluoGuide A/S | 543 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 18.03. | FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma | 414 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces... ► Artikel lesen | |
| 10.03. | Notice of Annual General Meeting in FluoGuide A/S | 528 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025 | 673 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Interim Report For Q4 2025 | 418 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report... ► Artikel lesen | |
| 20.02. | FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track | 785 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer... ► Artikel lesen | |
| 19.02. | Invitation to FluoGuide A/S Live Webcast on 25 February 2026 | 326 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 21.01. | FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial | 381 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 510 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,760 | +0,12 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Siemens Healthineers von 45 auf 48 Euro angehoben und die Einstufung auf "Outperform" belassen. Der Start des neuen Strahlentherapiesystems... ► Artikel lesen | |
| FRESENIUS | 45,305 | -0,64 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius vor Quartalszahlen auf "Buy" mit einem Kursziel von 56 Euro belassen. Der Medizinkonzern dürfte einmal mehr ein... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,180 | +1,90 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC nach Gesprächen mit dem Unternehmen mit einem Kursziel von 32,30 Euro auf "Underweight" belassen. Die Quartalszahlen des Dialysespezialisten... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,86 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| HEARTFLOW | 55,44 | +0,01 % | Piper Sandler raises HeartFlow stock price target on competitive moat | ||
| GERRESHEIMER | 32,000 | -0,25 % | Gerresheimer-Aktie: Trotz der deutlichen Kurserholung noch einsteigen? | Die Gerresheimer-Aktie entwickelt sich seit dem Kurseinbruch im Februar sehr erfreulich. Notierte sie damals noch bei etwa 16 €, steht sie am Montag aktuell bei rund 30,10 €. Damit hat sich der Kurs... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,565 | +0,04 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| CARL ZEISS MEDITEC | 35,100 | +2,57 % | 12 Prozent bessere Testleistung: Wie ZEISS das Zusammenspiel von Brillenglas und Gehirn untersucht | ||
| CONCENTRA GROUP | 39,970 | 0,00 % | Stephens initiates Concentra stock with overweight on health model | ||
| PROGYNY | 29,120 | 0,00 % | Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report | ||
| AVEANNA HEALTHCARE | 13,310 | -0,08 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,010 | -0,10 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| KESTRA MEDICAL TECHNOLOGIES | 28,310 | -0,04 % | Kestra Medical Technologies: Evercore-Einstufung treibt Aktie vorbörslich an | ||
| ALIGNMENT HEALTHCARE | 8,430 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors | ||
| GENEDX | 67,26 | 0,00 % | GeneDx plans to add long-read genome sequencing to portfolio |
Das Unternehmen FLUOGUIDE A/S kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 2,630 Euro und damit +1,94 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.